Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Durability of Antiplatelet Effect of a Novel Extended-Release Formulation of Acetylsalicylic Acid, Durlaza in CVD (Cardiovascular Disease) Patients at Risk of High Platelet Turnover

NCT02370680 is registered in ClinicalTrials.gov with New Haven Pharmaceuticals, Inc. as lead sponsor.

NCT NCT02370680
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02370680 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Durability of Antiplatelet Effect of a Novel Extended-Release Formulation of Acetylsalicylic Acid, Durlaza in CVD (Cardiovascular Disease) Patients at Risk of High Platelet Turnover
Lead sponsor
New Haven Pharmaceuticals, Inc.
Phase
Phase 1
Overall status
Completed
Start date
February 28, 2015
Completion date
July 31, 2015
Enrollment
41 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cardiovascular disease